Companies /Healthcare

Intellia Therapeutics Inc

NASDAQ: NTLA Biotechnology
$12.74
▲ $0.06 (+0.47%) today
Markets closed · 4:32pm ET

Q2 2025 Earnings

Reported Aug 7, 2025, 7:45am ET · SEC source
$-0.98
Beat +2.51%
EPS · est. $-1.01
$14.2M
Beat +17.12%
Revenue · est. $12.2M
+0.8%
Beating market
NTLA vs S&P since report
7 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−8%−4%0+4%Aug 7Aug 8report 7:45am ETearnings+0.1%−6.5%
−8%−4%0+4%Aug 7Aug 8earnings+0.1%−6.5%
NTLA −6.5%S&P 500 +0.1%
−8%−4%0+4%Aug 7Aug 8report 7:45am ETearnings+0.5%−6.5%
−8%−4%0+4%Aug 7Aug 8earnings+0.5%−6.5%
NTLA −6.5%NASDAQ +0.5%
−4%0+4%Aug 6Aug 15report 7:45am ETearnings+1.6%−4.1%
−4%0+4%Aug 6Aug 15earnings+1.6%−4.1%
NTLA −4.1%S&P 500 +1.6%
−4%0+4%Aug 6Aug 15report 7:45am ETearnings+1.5%−4.1%
−4%0+4%Aug 6Aug 15earnings+1.5%−4.1%
NTLA −4.1%NASDAQ +1.5%
+0.79%
Day of report
−5.85%
Next session
−4.89%
One week
+3.66%
30 days

S&P 500 over the same 30 days: +2.86%.

Did NTLA Beat Earnings? Q2 2025 Results

Intellia Therapeutics delivered a stronger-than-expected second quarter, beating both the top and bottom lines as collaboration revenue more than doubled year-over-year. The gene-editing company posted a loss of $0.98 per share, coming in ahead of the $1.01 consensus estimate by 2.51%, while revenue of $14.24 million topped expectations by 17.12% and surged 104.8% from a year ago. The primary driver was higher cost reimbursements from Regeneron Pharmaceuticals under their ATTR amyloidosis partnership, which fueled the collaboration revenue jump. Simultaneously, R&D expenses fell to $97.03 million from $114.21 million a year ago, helping narrow the net loss to $101.25 million compared to $146.97 million in Q2 2024. Looking ahead, management's $630.51 million cash position is expected to fund operations into the first half of 2027 and through its anticipated first commercial launch, with enrollment in the Phase 3 MAGNITUDE trial tracking ahead of schedule and BLA submission for lonvo-z in hereditary angioedema targeted for the second half of 2026.

Key Takeaways
  • Increased collaboration revenue from Regeneron cost reimbursements
  • Reduced R&D expenses from lower employee-related costs and stock-based compensation
  • Lower G&A expenses from reduced stock-based compensation
  • Higher interest income partially offset by lower fair value of investments

“We are exceeding many of our internal expectations. The enthusiasm from both patients and physicians for Intellia's late-stage programs has resulted in strong enrollment numbers that allow us to plan to enhance the Phase 3 MAGNITUDE trial in ATTR-CM and accelerate completion of the Phase 3 HAELO study in HAE ahead of our original plans. We are full steam ahead in achieving our mission of getting one-time therapies to more patients.”

Intellia Therapeutics CEO, on the earnings call

Forward Guidance & Outlook

Intellia expects its cash, cash equivalents, and marketable securities of approximately $630.5 million as of June 30, 2025 to fund operations into the first half of 2027 and into the anticipated first commercial launch. Key upcoming milestones include completing randomization in the Phase 3 HAELO study of lonvo-z in HAE during Q3 2025, enrolling at least 650 patients cumulatively in the MAGNITUDE trial by year-end 2025, completing enrollment in the MAGNITUDE-2 study by first half 2026, and submitting a BLA for lonvo-z in the second half of 2026. Additional clinical data from ongoing Phase 1/2 studies is expected in the second half of 2025.

NTLA YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$-120,000,000$-80,000,000$-40,000,000$0$7.0M$14.2MRevenue$-90,988,502$-109,996,000Operating Income$-77,229,044$-101,255,000Net Income
$-120,000,000$-80,000,000$-40,000,000$0RevenueOperating IncomeNet Income

NTLA Revenue by Segment

Collaboration Revenue
Collaboration Revenue (Regeneron)

Figures from SEC filings and company reports. Not investment advice.